2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Notes to the consolidated fi nancial statements 17. SEGMENT INFORMATION (CONTINUED) 100 2011 Nutraceuticals $’000’s Pharmaceuticals $’000’s Total all Segments $’000s Unallocated $’000’s Total Group $’000’s Revenue Sales and Royalties 2,738 6 2,744 - 2,744 Grant Income 105 - 105 1,131 1,236 Total segment revenue 2,843 6 2,849 1,131 3,980 Net operating profit/(loss) after tax (63) (1,513) (1,576) 2,682 1,106 Interest revenue - - - 427 427 Depreciation and amortisation - (67) (67) (2,583) (2,650) Segment assets 3,023 878 3,901 72,676 76,577 Capital Expenditure - - - 90 90 Segment liabilities 645 1,562 2,207 1,424 3,631 Cash flow information Net cash fl ow from Operating activities (2,260) (741) (3,001) (6,292) (9,293) Net cash fl ow from investing activities - 971 971 137 1,108 Net cash fl ow from fi nancing activities - - - 32,641 32,641 i) Segment revenue reconciliation to the statement of comprehensive income Reconciliation of revenue 2012 $’000 2011 $’000 Total segment revenue 1,530 2,849 Other revenue from continuing activities 1,133 427 Total revenue 2,663 3,276 Revenue from external customers by geographical locations is detailed below. Revenue is attributed to geographic location based on the location of the customers. Revenue by geographical location 2012 $’000 2011 $’000 Australia 1,632 2,074 United States 968 733 Other 63 469 Total revenue 2,663 3,276 ii) Segment net operating profit after tax reconciliation to the statement of comprehensive income The executive management committee meets on a monthly basis to assess the performance of each segment by analysing the segment’s net operating profi t after tax. A segment’s net operating profi t after tax excludes non operating income and expense such as dividends received, fair value gains and losses, gains and losses on disposal of assets and impairment charges. Income tax expenses are calculated as 30% (2011: 30%) of the segment’s net operating profi t. PHOSPHAGENICS ANNUAL REPORT 2012
Notes to the consolidated fi nancial statements 17. SEGMENT REVENUE (CONTINUED) Reconciliation of segment net operating profit after tax to net profit/loss before tax 2012 $’000 2011 $’000 Segment net operating profi t/(loss) after tax (1,421) (1,576) Other operating loss from continuing activities (4,836) (8,602) Amortisation (4,798) (2,546) Net loss on disposal of plant and equipment - - Total net profi t before tax per the statement of comprehensive income (11,055) (12,724) iii) Segment assets reconciliation to the statement of financial position In assessing the segment performance on a monthly basis, the executive management committee analyses the segment as described above and its relation to the segment assets. Segment assets are those operating assets of the entity that the management committee views as directly attributing to the performance of the segment. These assets include plant and equipment, receivables, inventory and intangibles and exclude available-for-sale assets, derivative assets and deferred tax assets. Reconciliation of segment operating assets to total assets 2012 $’000 2011 $’000 Segment operating assets 3,824 3,901 Other operating assets from continuing activities Intangibles 39,970 44,657 Cash & cash equivalents 16,912 27,196 All other operating assets from continuing activities 3,415 823 Total assets per the statement of fi nancial position 64,121 76,577 101 The analysis of the location of non-current assets other than fi nancial instruments, deferred tax assets, pension assets is as follows Non-current assets by geographical location 2012 $’000 2011 $’000 Australia 41,002 45,816 United States 2 2 Total assets 41,004 45,818 iv) Segment liabilities reconciliation to the statement of financial position Segment liabilities include trade and other payables and debt. The Group has a centralised fi nance function that is responsible for raising debt and capital for the entire operations. Each entity or business uses this central function to invest excess cash or obtain funding for its operations. Reconciliation of segment operating liabilities to total liabilities 2012 $’000 2011 $’000 Segment operating liabilities 555 2,207 Deferred tax liabilities - - Other operating liabilities from continuing activities 954 1,424 Total liabilities per the statement of fi nancial position 1,509 3,631 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Page 1 and 2:
20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4:
highlights March... April... May...
Page 5 and 6:
03 Jonathan Addison Chairman & Inde
Page 7 and 8:
COLLABORATIONS Strategic Collaborat
Page 9 and 10:
The Phosphagenics Evolution THE STO
Page 11 and 12:
“ We also reached agreement with
Page 13 and 14:
Overview of our opioid development
Page 15 and 16:
13 is branded as Butrans or Norspan
Page 17 and 18:
Personal Care ASHLAND INC (FORMERLY
Page 19 and 20:
BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21 and 22:
cellulite contour crème BioElixia
Page 23 and 24:
Intellectual Property Title Countri
Page 25 and 26:
2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28:
DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30:
Senior Management DR PAUL GAVIN Chi
Page 31 and 32:
Phosphagenics Limited ABN 32 056 48
Page 33 and 34:
Directors’ Report Your directors
Page 35 and 36:
Directors’ Report continued Looki
Page 37 and 38:
Directors’ Report continued Commi
Page 39 and 40:
Directors’ Report continued REMUN
Page 41 and 42:
Directors’ Report continued REMUN
Page 43 and 44:
Directors’ Report continued Share
Page 45 and 46:
Directors’ Report continued Share
Page 47 and 48:
Exercise Price Expiry Date Net othe
Page 49 and 50:
Exercise Price Expiry Date Net othe
Page 51 and 52: Fair value per performance right at
Page 53 and 54: Directors’ Report continued REMUN
Page 55 and 56: Auditors Independence Declaration 5
Page 57 and 58: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70: Consolidated statement of changes i
Page 71 and 72: Notes to the consolidated fi nancia
Page 73 and 74: Application date of standard Impact
Page 101: Notes to the consolidated fi nancia
Page 113 and 114: Independent Auditor’s Report 111
Page 115 and 116: Additional Shareholder Information
Page 117 and 118: Additional Shareholder Information
Page 119: corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?